DA-3003-1 NEW
| Price | $40 |
| Package | 1mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-27 |
Product Details
| Product Name: DA-3003-1 | CAS No.: 383907-43-5 |
| Purity: 99.79% | Supply Ability: 10g |
| Release date: 2025/04/27 |
Product Introduction
Bioactivity
| Name | DA-3003-1 |
| Description | DA-3003-1 (DA-3003-1) is a membrane-permeable, potent and selective Cdc25 dual specificity phosphatase inhibitor with antitumor activity that inhibits Cdc25B2, Cdc25A, Cdc25B2 and Cdc25C. |
| In vitro | DA-3003-1(DA-3003-1)(3-100 μM; 48 hours) exhibits an average IC50 value of 1.5 ± 0.6 μM across the NCI 60 cell panel of human tumor types. The IC50 values for human breast cancer MDA-MB-435 and MDA-N cells are 0.2 μM, while in cultured human breast MCF-7 cells, the IC50 value is 1.7 μM[1]. The relative IC50 value of DA-3003-1(DA-3003-1) against Cdc25B2 (IC50=0.21 μM) is lower than that against VHR (IC50 20 times lower and 450 times lower than 4.0 μM) or PTP1B (IC50>4.0 μM)[3]. |
| In vivo | DA-3003-1(DA-3003-1)(intravenous injection; 2, 3, and 5 mg/kg) inhibits the growth of subcutaneous human colon HT29 xenografts in SCID mice. Following a single dose of 5 mg/kg, DA-3003-1(DA-3003-1)is undetectable in plasma or tissues for more than 5 minutes. After treatment of HT29 tumor-bearing SCID mice with DA-3003-1(DA-3003-1), a greater reduction in glutathione concentration is observed in the tumor compared to the liver and kidneys, and this decrease persists for a longer duration[1]. |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (186.47 mM), Sonication is recommended. |
| Keywords | CDC25C | CDC25B2 | Cdc25B2 | CDC25A |
| Inhibitors Related | PTP1B-IN-22 | Disodium monofluorophosphate | β-Glycerophosphate disodium salt pentahydrate | Idoxuridine | Tartaric acid disodium dihydrate | Cyclosporine | Stearic acid | Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride | CaMKP Inhibitor | L-Ascorbic acid 2-phosphate magnesium | Trimyristin | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Bioactive Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Phosphatase Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/200kg |
VIP2Y
|
Qingdao RENAS Polymer Material Co., Ltd.
|
2024-10-28 | |
| $0.00/25KG |
VIP5Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2022-06-28 | |
| $0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-23 | |
| $1500.00/1g |
Wuhan Topule Biopharmaceutical Co., Ltd
|
2023-05-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY